OraSure (OSUR) 10-K 28 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 23, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	1,116,463
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		60,966,866
Entity Public Float			$ 1,010,050,592

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 71,029	$ 107,959
Restricted cash	1,840	1,831
Short-term investments	83,028	11,160
Accounts receivable, net of allowance for doubtful accounts of $471 and $484	42,521	19,827
Inventories	19,343	11,799
Prepaid expenses	1,658	1,722
Other current assets	2,486	2,143
Total current assets	221,905	156,441
PROPERTY AND EQUIPMENT, net	21,372	20,033
INTANGIBLE ASSETS, net	8,223	10,337
GOODWILL	20,083	18,793
LONG TERM INVESTMENTS	20,690
OTHER ASSETS	3,928	2,331
TOTAL ASSETS	296,201	207,935
CURRENT LIABILITIES:
Accounts payable	10,228	4,633
Deferred revenue	1,314	1,388
Accrued expenses	20,695	11,314
Total current liabilities	32,237	17,335
OTHER LIABILITIES	3,932	2,304
DEFERRED INCOME TAXES	1,951	2,446
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 60,662 and 56,001 shares issued and outstanding	0	0
Additional paid-in capital	387,931	350,528
Accumulated other comprehensive loss	(10,340)	(14,220)
Accumulated deficit	(119,510)	(150,458)
Total stockholders' equity	258,081	185,850
Total liabilities and stockholders' equity	$ 296,201	$ 207,935

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 471	$ 484
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	60,662,000	56,001,000
Common stock, shares outstanding	60,662,000	56,001,000

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
NET REVENUES:
Product	$ 161,988	$ 106,924	$ 104,458
Other	5,076	21,274	15,261
Total revenue	167,064	128,198	119,719
COST OF PRODUCTS SOLD	68,108	40,171	39,426
Gross profit	98,956	88,027	80,293
OPERATING EXPENSES:
Research and development	13,365	9,754	11,654
Sales and marketing	28,532	29,652	35,088
General and administrative	29,321	28,356	25,493
Gain on litigation settlement	(12,500)
Total operating expenses	58,718	67,762	72,235
Operating income	40,238	20,265	8,058
OTHER INCOME	794	58	774
Income before income taxes	41,032	20,323	8,832
INCOME TAX EXPENSE	10,084	603	665
NET INCOME	$ 30,948	$ 19,720	$ 8,167
EARNINGS PER SHARE:
BASIC	$ 0.52	$ 0.35	$ 0.14
DILUTED	$ 0.51	$ 0.35	$ 0.14
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	59,050	55,615	56,397
DILUTED	61,024	56,513	56,846

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
NET INCOME	$ 30,948	$ 19,720	$ 8,167
OTHER COMPEHENSIVE INCOME (LOSS)
Currency translation adjustments	4,433	1,419	(7,791)
Unrealized loss on marketable securities	(553)
COMPREHENSIVE INCOME	$ 34,828	$ 21,139	$ 376

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2014	$ 158,701		$ 344,894	$ (7,848)	$ (178,345)
Beginning Balance, Shares at Dec. 31, 2014		56,187
Common stock issued upon exercise of options	$ 404		404
Common stock issued upon exercise of options, Shares	74	74
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		354
Purchase and retirement of common shares	(6,090)		(6,090)
Purchase and retirement of common shares, Shares		(910)
Compensation cost for restricted stock	2,642		2,642
Compensation cost for stock option grants	3,403		3,403
NET INCOME	8,167				8,167
Currency translation adjustments	(7,791)			(7,791)
Ending Balance at Dec. 31, 2015	159,436		345,253	(15,639)	(170,178)
Ending Balance, Shares at Dec. 31, 2015		55,705
Common stock issued upon exercise of options	$ 2,656		2,656
Common stock issued upon exercise of options, Shares	405	405
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		446
Purchase and retirement of common shares	(3,444)		(3,444)
Purchase and retirement of common shares, Shares		(555)
Compensation cost for restricted stock	2,861		2,861
Compensation cost for stock option grants	2,691		2,691
Compensation cost for performance stock units	511		511
NET INCOME	19,720				19,720
Currency translation adjustments	1,419			1,419
Ending Balance at Dec. 31, 2016	185,850		350,528	(14,220)	(150,458)
Ending Balance, Shares at Dec. 31, 2016		56,001
Common stock issued upon exercise of options	$ 31,670		31,670
Common stock issued upon exercise of options, Shares	4,413	4,413
Vesting of restricted stock	$ 0	$ 0	0	0	0
Vesting of restricted stock, Shares		378
Purchase and retirement of common shares	(1,240)		(1,240)
Purchase and retirement of common shares, Shares		(130)
Compensation cost for restricted stock	2,705		2,705
Compensation cost for stock option grants	2,045		2,045
Compensation cost for performance stock units	2,223		2,223
NET INCOME	30,948				30,948
Currency translation adjustments	4,433			4,433
Unrealized loss on marketable securities	(553)			(553)
Ending Balance at Dec. 31, 2017	$ 258,081		$ 387,931	$ (10,340)	$ (119,510)
Ending Balance, Shares at Dec. 31, 2017		60,662

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
OPERATING ACTIVITIES:
NET INCOME	$ 30,948	$ 19,720	$ 8,167
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	6,973	6,063	6,045
Depreciation and amortization	6,402	5,640	5,806
Unrealized foreign currency loss	156	122	367
Loss (gain) on sale of fixed assets	(25)	(28)	80
Deferred income taxes	(649)	(529)	48
Changes in assets and liabilities
Accounts receivable	(22,116)	(576)	(3,739)
Inventories	(7,391)	1,476	2,348
Prepaid expenses and other assets	(384)	(652)	(1,415)
Accounts payable	5,157	46	(2,648)
Deferred revenue	(93)	(8,350)	1,706
Accrued expenses and other liabilities	9,178	1,666	(992)
Net cash provided by operating activities	28,156	24,598	15,773
INVESTING ACTIVITIES:
Purchases of investments	(161,269)	(34,133)	(26,895)
Proceeds from maturities and redemptions of investments	69,253	30,421	23,934
Purchases of property and equipment	(4,337)	(4,353)	(3,744)
Net cash used in investing activities	(96,353)	(8,065)	(6,705)
FINANCING ACTIVITIES:
Payments for debt issue costs		(367)
Proceeds from exercise of stock options	31,675	2,656	404
Repurchase of common stock	(1,240)	(3,444)	(6,090)
Net cash provided by (used in) financing activities	30,435	(1,155)	(5,686)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	841	318	(2,155)
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(36,921)	15,696	1,227
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD	109,790	94,094	92,867
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD	$ 72,869	$ 109,790	$ 94,094

The Company

The Company	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. THE COMPANY: Our business is comprised of two segments: Our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro Our OSUR diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. We also manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery or freezing. These cryosurgical products are sold in both professional and over-the-counter Our “DNAG” or molecular collection systems business is operated by our subsidiary, DNA Genotek Inc., a company based in Ottawa, Canada. DNAG’s Oragene ® all-in-one TM

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods. Supplemental Cash Flow Information In 2017, 2016 and 2015, we paid income taxes of $4,309, $1,123 and $719, respectively. In 2017, 2016 and 2015, we recorded through the consolidated statements of income an increase in our allowance for doubtful accounts of $172, $40 and $341, respectively. We had $200 and $369 in write-offs against the allowance for doubtful accounts in 2017 and 2016, respectively. We had no material write-offs against the allowance for doubtful accounts in 2015. As of December 31, 2017, 2016 and 2015, we had accruals for purchases of property and equipment of $449, $302 and $1,256, respectively. Investments We consider all investments to be available-for-sale Available-for-sale The following is a summary of our available-for-sale Amortized Gross Gross Fair Value December 31, 2017 Guaranteed investment certificates $ 22,261 $ — $ — $ 22,261 Corporate bonds 82,010 — (553 ) 81,457 Total available-for-sale $ 104,271 $ — $ (553 ) $ 103,718 December 31, 2016 Guaranteed investment certificates $ 11,160 $ — $ — $ 11,160 Total available-for-sale $ 11,160 $ — $ — $ 11,160 At December 31, 2017 maturities of our available-for-sale Less than one year $ 83,403 $ — $ (375 ) $ 83,028 Greater than one year $ 20,868 $ — $ (178 ) $ 20,690 Accounts Receivable Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs. Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out Property and Equipment Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income. Intangible Assets Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of seven to fifteen years. Impairment of Long-Lived Assets We assess the recoverability of our long-lived assets, which include property and equipment and intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Goodwill Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit. We performed our annual impairment assessment as of July 31, 2017 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of December 31, 2017, we believe no indicators of impairment exist. Revenue Recognition We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for sales of our OraQuick ® In-Home Our net revenues recorded on sales of the OraQuick ® In-Home We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. On June 10, 2014, we entered into a Master Program Services and Co-Promotion co-promote ® co-promotion On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick ® ® In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, In June 2017, we entered into a four-year Charitable Support Agreement with the Bill & Melinda Gates Foundation (“Gates Foundation”) that will enable us to offer our OraQuick ® Customer Sales Returns and Allowances We do not grant return rights to our customers for any product, except for our OraQuick ® In-Home ® In-Home Deferred Revenue We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2017 and 2016 includes customer prepayments of $1,314 and $1,388, respectively. Customer and Vendor Concentrations One of our customers accounted for 37% and 15% of our accounts receivable as of December 31, 2017 and 2016, respectively. The same customer accounted for approximately 25% of our net consolidated revenues for the year ended December 31, 2017. Another customer accounted for approximately 15% and 12% of our net consolidated revenues for the years ended December 31, 2016 and 2015, respectively. We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations. Research and Development Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred. Advertising Expenses Advertising costs are charged to expense as incurred. During 2017, 2016, and 2015, we incurred $717, $626, and $623, respectively, in advertising expenses. Stock-Based Compensation We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than purchase shares in the open market. Income Taxes We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards. Foreign Currency Translation The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange (losses) gains resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(1,442), $(607), and $1,005 for the years ended December 31, 2017, 2016, and 2015, respectively. Earnings Per Share Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. The computations of basic and diluted earnings per share are as follows: Year ended December 31, 2017 2016 2015 Net income $ 30,948 $ 19,720 $ 8,167 Weighted average shares of common stock outstanding: Basic 59,050 55,615 56,397 Dilutive effect of stock options, restricted stock, and performance stock units 1,974 898 449 Diluted 61,024 56,513 56,846 Earnings per share: Basic $ 0.52 $ 0.35 $ 0.14 Diluted $ 0.51 $ 0.35 $ 0.14 For the years ended December 31, 2017, 2016, and 2015, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 180, 2,546, and 4,314 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. Accumulated Other Comprehensive Loss We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at December 31, 2017 consists of $9,787 of currency translation adjustments and $553 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio. Accumulated other comprehensive loss at December 31, 2016 consists of $14,220 of currency translation adjustments. Fair Value of Financial Instruments As of December 31, 2017 and 2016, the carrying values of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of our available-for-sale Included in cash and cash equivalents at December 31, 2017 and 2016, was $40,760 and $83,704 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments. We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2017 and 2016 was $3,514 and $1,980, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets. In 2017, we purchased certificates of deposit (“CDs”) from a commercial bank. The CDs bear interest at rates ranging from 0.89% to 1.03% and mature periodically through January 22, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 11 – Commitments and Contingencies. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09, Revenue from Contracts with Customers We have completed our evaluation of the new standard and have assessed the impacts of adoption on our consolidated financial statements and disclosures. Based on our evaluation of our current contracts and revenue streams, revenue recognition is mostly consistent under both the previous and new standard, with the exception of one revenue stream within our drug testing kits segment, which is described below. We believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations and the estimate of unexercised rights (“breakage”) associated with the contracts. Prior to the adoption of ASU 2014-09, 2014-09, The FASB allows two adoption methods under ASU 2014-09. The disclosures in our notes to the consolidated financial statements related to revenue recognition will be significantly expanded under the new standard, specifically around the quantitative and qualitative information about performance obligations, changes in contract assets and liabilities, and disaggregation of revenue. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory first-in, first-out 2015-11 In February 2016, the FASB issued ASU 2016-02, Leases 2016-02 In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting 2016-09 2016-09 2016-09 In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments 2016-15 In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment 2017-04 In March 2017, the FASB issued ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): non-contingently 2017-08 In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting

Inventories

Inventories	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventories	3. INVENTORIES: December 31, 2017 2016 Raw materials $ 10,299 $ 5,399 Work in process 199 1,034 Finished goods 8,845 5,366 $ 19,343 $ 11,799

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	4. PROPERTY AND EQUIPMENT: December 31, 2017 2016 Land $ 1,118 $ 1,118 Buildings and improvements 20,726 20,179 Machinery and equipment 26,685 22,764 Computer equipment and software 9,131 8,357 Furniture and fixtures 2,194 2,113 Construction in progress 897 1,569 60,751 56,100 Less accumulated depreciation (39,379 ) (36,067 ) $ 21,372 $ 20,033 Depreciation expense was $3,434, $3,149, and $2,992 for 2017, 2016, and 2015, respectively.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	5. GOODWILL AND OTHER INTANGIBLE ASSETS: The changes in goodwill are as follows: December 31, 2017 2016 Balance as of January 1 $ 18,793 $ 18,250 Change related to foreign currency translation 1,290 543 Balance as of December 31 $ 20,083 $ 18,793 Intangible assets consist of the following: December 31, 2017 Amortization Gross Accumulated Net Customer list 10 $ 9,960 $ (6,122 ) $ 3,838 Patents and product rights 10 5,400 (4,258 ) 1,142 Acquired technology 7 7,737 (6,690 ) 1,047 Tradename 15 3,818 (1,622 ) 2,196 $ 26,915 $ (18,692 ) $ 8,223 December 31, 2016 Amortization Gross Accumulated Net Customer list 10 $ 9,321 $ (4,830 ) $ 4,491 Patents and product rights 10 5,400 (3,808 ) 1,592 Acquired technology 7 7,240 (5,279 ) 1,961 Tradename 15 3,573 (1,280 ) 2,293 $ 25,534 $ (15,197 ) $ 10,337 Patents and products rights are made up of the following: December 31, 2017 2016 HIV-related $ 900 $ 900 HCV-related 4,500 4,500 5,400 5,400 Less accumulated amortization (4,258 ) (3,808 ) $ 1,142 $ 1,592 Amortization expense for 2017, 2016, and 2015 was $2,641, $2,538, and $2,704, respectively. Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows: 2018 $ 2,639 2019 1,626 2020 1,417 2021 1,173 2022 246 Beyond 1,122 $ 8,223

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	6. ACCRUED EXPENSES: December 31, 2017 December 31, 2016 Payroll and related benefits $ 9,265 $ 7,685 Income taxes payable (receivable) 6,469 (39 ) Professional fees 1,064 982 Royalties 845 715 Other 3,052 1,971 $ 20,695 $ 11,314

Credit Facility

Credit Facility	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Credit Facility	7. CREDIT FACILITY: On September 30, 2016, we entered into a credit agreement (the “Credit Agreement”) with a commercial bank. The Credit Agreement, as amended on December 20, 2017, provides for revolving extensions of credit in an initial aggregate amount of up to $10,000 (inclusive of a letter of credit sub-facility Borrowings under the Credit Agreement are subject to compliance with borrowing base limitations tied to eligibility of accounts receivable. Interest under the Credit Agreement is payable at the London Interbank Offered Rate for one, two, three or six-month In connection with the Credit Agreement, under certain circumstances, we must comply with a minimum fixed charge coverage ratio of 1.10 to 1.00, measured as of the last day of each fiscal month and for the twelve-fiscal month period ending on such date. As of December 31, 2017 and 2016, we were in compliance with all applicable covenants in the Credit Agreement.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	8. INCOME TAXES: Income before income tax expense consists of the following: Years Ended December 31, 2017 2016 2015 United States $ 2,270 $ 18,492 $ 5,302 Canada 38,762 1,831 3,530 $ 41,032 $ 20,323 $ 8,832 The components of income tax expense are as follows: Years Ended December 31, 2017 2016 2015 Current Federal $ — $ — $ — State — 250 — Canada 10,733 882 617 10,733 1,132 617 Deferred Federal 10,297 6,508 1,511 State (827 ) 569 311 Canada (649 ) (529 ) 48 8,821 6,548 1,870 Decrease in valuation allowance (9,470 ) (7,077 ) (1,822 ) (649 ) (529 ) 48 Total income tax expense $ 10,084 $ 603 $ 665 For the years ended December 31, 2017, 2016, and 2015 we recorded foreign income tax expense of $10,084, $353, and $665, respectively. The Tax Cuts and Jobs Act On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (“Tax Act”) that instituted fundamental changes to the taxation on multinational corporations. Although the Tax Act is generally effective January 1, 2018, U.S. generally accepted accounting principles requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017. Among the numerous provisions, the Tax Act includes two provisions in particular which require consideration for 2017 financial reporting: a permanent reduction in the corporate tax rate to 21%; and a one-time The reduction in the U.S. corporate tax rate to 21% is effective in 2018. However, this change results in a re-measurement The one-time In addition, the Tax Act also includes changes to the taxation of foreign earnings by implementing a dividend exemption system, expansion of the current anti-deferral rules, a minimum tax on low-taxed As a result of the complex impact of the Tax Act, the SEC provided guidance under Staff Accounting Bulletin No. 118 (“SAB 118”) that allows the Company to record provisional amounts as of December 31, 2017 for the impact of the Tax Act, provided that the provisional amounts can be reasonably determined and with the requirement that the final accounting be completed in a period not to exceed one year from the date of enactment. As of December 31, 2017, the Company has not completed the accounting for the tax effects of the Tax Act, and therefore, has recorded provisional amounts which include: (a) An estimate of the impact of the one-time (b) The valuation allowance for the Company’s deferred tax assets as of December 31, 2017, is primarily dependent on forecasted future taxable income in the U.S. and Canada and may be impacted by the provisions of the Tax Act. Any increase or reduction in estimated forecasted future taxable income may require the Company to adjust the valuation allowance against the remaining deferred tax asset. The Company will continue to assess the impact of the Tax Act on the valuation allowance during the provisional period. The Tax Act imposes a U.S. tax on global intangible low taxed income (“GILTI”) that is earned by certain foreign affiliates owned by a U.S. shareholder effective in 2018. GILTI is generally intended to impose tax on the earnings of a foreign corporation that are deemed to exceed a certain threshold return relative to the underlying tangible property. The computation of GILTI is still subject to interpretation and additional clarifying guidance is expected. The Company has not yet made a policy election related to its treatment of GILTI as either a current period expense in the reporting period in which the tax is incurred or recognizing deferred taxes when a basis differences exists that is expected to affect the amount of the GILTI inclusion upon reversal. The Company is still in the process of analyzing the expected impact of GILTI in future periods. A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2017, 2016, and 2015 is as follows: 2017 2016 2015 Statutory U.S. federal income tax rate 34.0 % 34.0 % 34.0 % Deemed repatriation tax 7.8 — — Statutory rate change, deferred tax impact 29.4 — — Excess tax benefits for share-based payment awards (16.0 ) — — Tax effect of Canadian items (9.8 ) (4.9 ) (13.1 ) State income taxes, net of federal benefit (1.1 ) 2.0 1.5 Nondeductible expenses and other 3.4 6.7 5.7 Change in valuation allowance, federal and state (23.1 ) (34.8 ) (20.6 ) Effective tax rate 24.6 % 3.0 % 7.5 % Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our deferred tax assets (liabilities) as of December 31, 2017 and 2016 are as follows: 2017 2016 Deferred tax assets (liabilities): Net operating loss carryforwards $ 15,338 $ 17,673 Inventories 1,179 1,680 Capitalized research and development costs 2,402 4,711 Accruals and reserves currently not deductible 3,103 3,282 Acquired intangible assets (1,825 ) (2,268 ) Depreciation and amortization (621 ) (212 ) Stock-based compensation 976 6,110 Tax credit carryforwards 6,722 1,751 Net deferred tax asset 27,274 32,727 Valuation allowance (29,225 ) (35,173 ) Net deferred tax liability $ (1,951 ) $ (2,446 ) In assessing the realizability of our deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, we established a full valuation allowance against our U.S. deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2017 and 2016 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2017, 2016, or 2015. The valuation allowance primarily decreased by $9,470 in 2017 due to its re-measurement Our Federal NOL carryforwards expire as follows: Year of Expiration NOLs 2020 - 2025 $ 16,268 2026 - 2030 11,956 2031 - 2037 37,937 $ 66,161 The new accounting guidance under ASU 2016-09 The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 that limit the annual amount of federal and state NOL carryforwards that can be used in any given year in the event a significant change in ownership. The Company does not believe that there is a Section 382 limitation that will impair our future ability to utilize NOLs to offset our future taxable income. The Company continues to review ownership changes on an annual basis and we do not believe we have had a subsequent ownership change that would impact the NOLs. Effective January 1, 2018, there is a transition to a participation exemption system whereby distributions from foreign subsidiaries to U.S. shareholders are generally exempt from taxation; therefore, the deferred tax liability on undistributed earnings is limited to any foreign withholding or other local taxes. The Company’s intention is to continue to permanently reinvest the historical undistributed earnings of our Canadian subsidiary to the extent that we will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As of December 31, 2017, our gross unrecognized tax benefits totaled $1,663, and based upon the valuation allowance for our U.S. operations, the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2017, 2016 and 2015. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended September 30, 1998 through December 31, 2017. A reconciliation of our unrecognized tax benefits is as follows: 2017 2016 2015 Balance as of January 1 $ 2,084 $ 2,088 $ 2,073 Additions for tax positions of prior periods — — 22 Reductions for tax positions of prior periods (421 ) (4 ) (7 ) Balance as of December 31 $ 1,663 $ 2,084 $ 2,088

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Equity	9. STOCKHOLDERS’ EQUITY: Stock-Based Awards We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. As of December 31, 2017, 4,355 shares were available for future grants under the Stock Plan. Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions: Years Ended December 31, Black-Scholes Option Valuation Assumptions 2017 2016 2015 Risk-free interest rate (1) 2.22 % 1.76 % 1.49 % Expected dividend yield — — — Expected stock price volatility (2) 43 % 46 % 51 % Expected life of stock options (in years) (2) 7 7 7 (1) Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options. (2) Based upon historical experience. The weighted-average grant date fair value of stock options granted during the years ended December 31, 2017, 2016 and 2015 was $4.71, $2.91 and $4.86, respectively. Compensation expense recognized in the financial statements related to stock options was as follows: Years Ended December 31, 2017 2016 2015 Total compensation cost during the year $ 2,045 $ 2,691 $ 3,403 Amounts capitalized into inventory during the year (371 ) (270 ) (153 ) Amounts recognized in cost of products sold for amounts previously capitalized 276 212 153 Amounts charged against income $ 1,950 $ 2,633 $ 3,403 The aggregate intrinsic value of options exercised during the years ended December 31, 2017, 2016, and 2015 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $35,631, $763, and $329, respectively. The following table summarizes the stock option activity under the Stock Plan: Options Weighted-Average Weighted-Average Aggregate Outstanding on January 1, 2015 5,740 $ 7.22 Granted 773 9.28 Exercised (74 ) 5.46 Expired (163 ) 8.55 Forfeited (60 ) 8.07 Outstanding on December 31, 2015 6,216 7.46 Granted 347 6.00 Exercised (405 ) 6.57 Expired (479 ) 9.17 Forfeited (223 ) 7.31 Outstanding on December 31, 2016 5,456 7.28 Granted 231 9.92 Exercised (4,413 ) 7.20 Expired (27 ) 8.36 Forfeited (46 ) 7.79 Outstanding on December 31, 2017 1,201 $ 8.04 6.5 $ 12,986 Vested or expected to vest as of December 31, 2017 1,201 $ 8.04 6.5 $ 12,986 Exercisable on December 31, 2017 659 $ 7.81 5.2 $ 7,280 As of December 31, 2017, there was $1,950 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 1.9 years. Net cash proceeds from the exercise of stock options were $31,675, $2,656 and $404 for the years ended December 31, 2017, 2016, and 2015, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods. The following table summarizes information about stock options outstanding as of December 31, 2017: Options outstanding Options exercisable Range of exercise prices Number Weighted- (in years) Weighted- Number Weighted- $2.79 -$5.19 19 0.3 $ 3.46 19 $ 3.46 $5.37 158 8.0 5.37 45 5.37 $5.47 3 7.7 5.47 1 5.47 $5.71 149 5.9 5.71 116 5.71 $5.79 - $7.05 138 4.5 6.73 130 6.74 $7.28 - $8.33 122 6.4 7.81 95 7.74 $8.33 - $8.63 41 1.9 8.62 41 8.62 $8.87 167 8.9 8.87 — 0.00 $8.93 6 9.0 8.93 — 0.00 $9.31 - $14.95 398 6.5 10.32 212 10.40 1,201 6.5 $ 8.04 659 $ 7.81 The Stock Plan also permits us to grant restricted shares of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by our Compensation Committee or Board of Directors. The market value of these shares at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $2,705, $2,861 and $2,642 related to restricted shares was recognized during the years ended December 31, 2017, 2016, and 2015, respectively. The following table summarizes restricted stock award activity under the Stock Plan: Units Weighted-Average Issued and unvested, January 1, 2015 707 $ 6.50 Granted 362 8.25 Vested (354 ) 6.94 Forfeited (18 ) 8.01 Issued and unvested, December 31, 2015 697 7.14 Granted 632 5.63 Vested (446 ) 6.65 Forfeited (133 ) 6.43 Issued and unvested, December 31, 2016 750 6.28 Granted 329 9.77 Vested (378 ) 6.47 Forfeited (30 ) 7.57 Issued and unvested, December 31, 2017 671 $ 7.83 Issued and expected to vest, December 31, 2017 671 $ 7.83 As of December 31, 2017, there was $2,910 of unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.7 years. In connection with the vesting of restricted shares and exercise of stock options during the years ended December 31, 2017, 2016 and 2015, we purchased and immediately retired 130, 132 and 133 shares with aggregate values of $1,240, $784 and $1,164, respectively, in satisfaction of minimum tax withholding and exercise obligations. Commencing in 2016, we granted performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year one-year one-year one-year Compensation cost of $2,223 and $511 related to the PSUs was recognized during the years ended December 31, 2017 and 2016, respectively. The following table summarizes PSU activity under the Stock Plan: Units Weighted- Issued and unvested, January 1, 2017 456 5.46 Granted 424 8.19 Vested 0 0.00 Forfeited (28 ) 6.71 Issued and unvested, December 31, 2017 852 $ 6.78 Issued and expected to vest, December 31, 2017 852 $ 6.78 Share Repurchase Program On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired in 2017. During the years ended December 31, 2016 and 2015, we purchased and retired 423 and 777 shares of common stock at an average price of $6.29 and $6.34 per share for a total cost of $2,660 and $4,926, respectively.

Business Segment Information

Business Segment Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Business Segment Information	10. BUSINESS SEGMENT INFORMATION: Our business is comprised of two segments: Our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated. The following table summarizes operating segment information for the years ended December 31, 2017, 2016, and 2015, and asset information as of December 31, 2017 and 2016: Years Ended December 31, 2017 2016 2015 Net revenues: OSUR $ 91,965 $ 95,984 $ 89,795 DNAG 75,099 32,214 29,924 Total $ 167,064 $ 128,198 $ 119,719 Operating income (loss): OSUR $ (2,706 ) $ 15,606 $ 3,558 DNAG 42,944 4,659 4,500 Total $ 40,238 $ 20,265 $ 8,058 Depreciation and amortization: OSUR $ 3,170 $ 2,751 $ 3,015 DNAG 3,232 2,889 2,791 Total $ 6,402 $ 5,640 $ 5,806 Capital expenditures: OSUR $ 2,752 $ 2,145 $ 1,645 DNAG 1,585 2,208 2,099 Total $ 4,337 $ 4,353 $ 3,744 December 31, 2017 2016 Total assets: OSUR $ 192,352 $ 151,719 DNAG 103,849 56,216 Total $ 296,201 $ 207,935 The following table represents total net revenues by geographic area, based on the location of the customer: Years Ended December 31, 2017 2016 2015 United States $ 121,458 $ 99,758 $ 96,522 Europe 11,827 11,646 13,535 Other regions 33,779 16,794 9,662 $ 167,064 $ 128,198 $ 119,719 The following table represents total long-lived assets by geographic area: December 31, 2017 2016 United States $ 16,160 $ 15,737 Canada 5,083 4,286 Other regions 129 10 $ 21,372 $ 20,033

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. COMMITMENTS AND CONTINGENCIES: Sublicense Agreement In June 2004, we entered into a sublicense agreement with a third party pursuant to which we have been granted a limited, worldwide, non-exclusive HIV-2 Leases We lease office space for our Canadian subsidiary and domestic warehouse facilities under operating lease agreements. Future payments required under these non-cancelable 2018 $ 617 2019 791 2020 828 2021 834 2022 845 Thereafter 1,242 $ 5,157 Rent expense for 2017, 2016 and 2015 was $852, $715, and $481, respectively. Purchase Commitments As of December 31, 2017, we had outstanding non-cancelable 2018 14,262 2019 383 2020 383 $ 15,028 Employment Agreements Under terms of employment agreements with certain employees, which extend through 2019, we are required to pay each individual a base salary for continuing employment with us. The agreements require payments totaling $1,729 and $330 in 2018 and 2019, respectively. Standby Letters of Credit We established standby letters of credit in the amount of $1,840, naming international customers as the beneficiaries. These letters of credit were required as a performance guarantee of our obligations under our product supply contracts with those customers and are collateralized by certificates of deposit maintained at a commercial bank. The standby letters of credit are recorded in restricted cash in the accompanying consolidated balance sheet. Litigation From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Retirement Plans	12. RETIREMENT PLANS: Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4 per year. We contributed $617, $619 and $587 to the 401(k) Plan, net of forfeitures, in 2017, 2016, and 2015, respectively. In addition to our 401(k) plan, we offer a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2017 and 2016, the value of the assets associated with this plan was $3,514 and $1,980, respectively, and is included in other assets in our consolidated balance sheets. Our obligation related to the deferred compensation plan is included in other liabilities in our consolidated balance sheets. As of December 31, 2017 and 2016, our total obligation under this plan was $3,514 and $1,980, respectively. Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $2 per year. We contributed $145, $134 and $134 to the RRSP in 2017, 2016, and 2015, respectively.

Quarterly Data

Quarterly Data	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Data	13. QUARTERLY DATA (Unaudited): The following tables summarize the quarterly results of operations for each of the quarters in 2017 and 2016. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein. 2017 Results Three months ended March 31, June 30, September 30, December 31, Net revenues $ 32,546 $ 40,176 $ 42,314 $ 52,028 Costs and expenses 16,675 (1) 33,289 34,995 41,867 Operating income 15,871 (1) 6,887 7,319 10,161 Other income, net 467 96 113 118 Income before income taxes 16,338 6,983 7,432 10,279 Income tax expense 3,897 1,555 1,669 2,963 Net income $ 12,441 $ 5,428 $ 5,763 $ 7,316 Earnings per share Basic $ 0.22 $ 0.09 $ 0.10 $ 0.12 (2) Diluted $ 0.21 $ 0.09 $ 0.09 $ 0.12 (2) 2016 Results Three months ended March 31, June 30, September 30, December 31, Net revenues $ 29,089 $ 31,359 $ 32,251 (3) $ 35,499 (3) Costs and expenses 26,390 27,010 26,107 28,426 Operating income 2,699 4,349 6,144 7,073 Other income (expense), net (192 ) (340 ) 498 92 Income before income taxes 2,507 4,009 6,642 7,165 Income tax expense (benefit) 61 173 400 (31 ) Net income $ 2,446 $ 3,836 $ 6,242 $ 7,196 Earnings per share Basic $ 0.04 $ 0.07 $ 0.11 $ 0.13 Diluted $ 0.04 $ 0.07 $ 0.11 $ 0.13 (1) Includes a $12,500 gain associated with the settlement of our litigation with Ancestry.com DNA LLC and its contract manufacturer, which was recorded as a reduction of operating expenses in the indicated period. (2) The summation of the quarterly amounts may not equal the year-end (3) Revenues in the last six months of 2016 include an additional $5,436 of exclusivity payments recognized in other revenues as a result of the early termination of our HCV co-promotion

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	14. SUBSEQUENT EVENTS: In January 2018, we announced the retirement of our President and Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”) and Chief Operating Officer. Stephen S. Tang, Ph.D., who currently serves as Chairman of the Board of Directors (the “Board”), was appointed as the Company’s new President and CEO, effective as of April 1, 2018. Dr. Tang will replace Douglas A. Michels, who will retire as President and CEO, and as a member of the Board, on March 31, 2018. In addition, Ronald H. Spair, our CFO and Chief Operating Officer, will be retiring on or before June 30, 2018, with his exact retirement date to be determined based on the timing for the Company’s appointment of a new CFO. Charges associated with these transitions are expected to total $8,590 in 2018. These charges primarily reflect non-cash

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
Supplemental Cash Flow Information	Supplemental Cash Flow Information In 2017, 2016 and 2015, we paid income taxes of $4,309, $1,123 and $719, respectively. In 2017, 2016 and 2015, we recorded through the consolidated statements of income an increase in our allowance for doubtful accounts of $172, $40 and $341, respectively. We had $200 and $369 in write-offs against the allowance for doubtful accounts in 2017 and 2016, respectively. We had no material write-offs against the allowance for doubtful accounts in 2015. As of December 31, 2017, 2016 and 2015, we had accruals for purchases of property and equipment of $449, $302 and $1,256, respectively.
Investments	Investments We consider all investments to be available-for-sale Available-for-sale The following is a summary of our available-for-sale Amortized Gross Gross Fair Value December 31, 2017 Guaranteed investment certificates $ 22,261 $ — $ — $ 22,261 Corporate bonds 82,010 — (553 ) 81,457 Total available-for-sale $ 104,271 $ — $ (553 ) $ 103,718 December 31, 2016 Guaranteed investment certificates $ 11,160 $ — $ — $ 11,160 Total available-for-sale $ 11,160 $ — $ — $ 11,160 At December 31, 2017 maturities of our available-for-sale Less than one year $ 83,403 $ — $ (375 ) $ 83,028 Greater than one year $ 20,868 $ — $ (178 ) $ 20,690
Accounts Receivable	Accounts Receivable Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income.
Intangible Assets	Intangible Assets Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of seven to fifteen years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets We assess the recoverability of our long-lived assets, which include property and equipment and intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets.
Goodwill	Goodwill Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit. We performed our annual impairment assessment as of July 31, 2017 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of December 31, 2017, we believe no indicators of impairment exist.
Revenue Recognition	Revenue Recognition We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for sales of our OraQuick ® In-Home Our net revenues recorded on sales of the OraQuick ® In-Home We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. On June 10, 2014, we entered into a Master Program Services and Co-Promotion co-promote ® co-promotion On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services (“HHS”) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick ® ® In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The six-year, In June 2017, we entered into a four-year Charitable Support Agreement with the Bill & Melinda Gates Foundation (“Gates Foundation”) that will enable us to offer our OraQuick ®
Customer Sales Returns and Allowances	Customer Sales Returns and Allowances We do not grant return rights to our customers for any product, except for our OraQuick ® In-Home ® In-Home
Deferred Revenue	Deferred Revenue We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2017 and 2016 includes customer prepayments of $1,314 and $1,388, respectively.
Customer and Vendor Concentrations	Customer and Vendor Concentrations One of our customers accounted for 37% and 15% of our accounts receivable as of December 31, 2017 and 2016, respectively. The same customer accounted for approximately 25% of our net consolidated revenues for the year ended December 31, 2017. Another customer accounted for approximately 15% and 12% of our net consolidated revenues for the years ended December 31, 2016 and 2015, respectively. We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Research and Development	Research and Development Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.
Advertising Expenses	Advertising Expenses Advertising costs are charged to expense as incurred. During 2017, 2016, and 2015, we incurred $717, $626, and $623, respectively, in advertising expenses.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than purchase shares in the open market.
Income Taxes	Income Taxes We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.
Foreign Currency Translation	Foreign Currency Translation The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange (losses) gains resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $(1,442), $(607), and $1,005 for the years ended December 31, 2017, 2016, and 2015, respectively.
Earnings Per Share	Earnings Per Share Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. The computations of basic and diluted earnings per share are as follows: Year ended December 31, 2017 2016 2015 Net income $ 30,948 $ 19,720 $ 8,167 Weighted average shares of common stock outstanding: Basic 59,050 55,615 56,397 Dilutive effect of stock options, restricted stock, and performance stock units 1,974 898 449 Diluted 61,024 56,513 56,846 Earnings per share: Basic $ 0.52 $ 0.35 $ 0.14 Diluted $ 0.51 $ 0.35 $ 0.14 For the years ended December 31, 2017, 2016, and 2015, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 180, 2,546, and 4,314 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at December 31, 2017 consists of $9,787 of currency translation adjustments and $553 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio. Accumulated other comprehensive loss at December 31, 2016 consists of $14,220 of currency translation adjustments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of December 31, 2017 and 2016, the carrying values of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of our available-for-sale Included in cash and cash equivalents at December 31, 2017 and 2016, was $40,760 and $83,704 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments. We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2017 and 2016 was $3,514 and $1,980, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets. In 2017, we purchased certificates of deposit (“CDs”) from a commercial bank. The CDs bear interest at rates ranging from 0.89% to 1.03% and mature periodically through January 22, 2018. The carrying values of the CDs approximate their fair value. These CDs serve as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets. Also see Note 11 – Commitments and Contingencies.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09, Revenue from Contracts with Customers We have completed our evaluation of the new standard and have assessed the impacts of adoption on our consolidated financial statements and disclosures. Based on our evaluation of our current contracts and revenue streams, revenue recognition is mostly consistent under both the previous and new standard, with the exception of one revenue stream within our drug testing kits segment, which is described below. We believe the key changes in the standard that impact our revenue recognition relate to the allocation of the transaction price to performance obligations and the estimate of unexercised rights (“breakage”) associated with the contracts. Prior to the adoption of ASU 2014-09, 2014-09, The FASB allows two adoption methods under ASU 2014-09. The disclosures in our notes to the consolidated financial statements related to revenue recognition will be significantly expanded under the new standard, specifically around the quantitative and qualitative information about performance obligations, changes in contract assets and liabilities, and disaggregation of revenue. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory first-in, first-out 2015-11 In February 2016, the FASB issued ASU 2016-02, Leases 2016-02 In March 2016, the FASB issued authoritative guidance under ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting 2016-09 2016-09 2016-09 In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments 2016-15 In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment 2017-04 In March 2017, the FASB issued ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): non-contingently 2017-08 In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Available-for-sale Securities	The following is a summary of our available-for-sale Amortized Gross Gross Fair Value December 31, 2017 Guaranteed investment certificates $ 22,261 $ — $ — $ 22,261 Corporate bonds 82,010 — (553 ) 81,457 Total available-for-sale $ 104,271 $ — $ (553 ) $ 103,718 December 31, 2016 Guaranteed investment certificates $ 11,160 $ — $ — $ 11,160 Total available-for-sale $ 11,160 $ — $ — $ 11,160 At December 31, 2017 maturities of our available-for-sale Less than one year $ 83,403 $ — $ (375 ) $ 83,028 Greater than one year $ 20,868 $ — $ (178 ) $ 20,690
Computations of Basic and Diluted Earnings Per Share	The computations of basic and diluted earnings per share are as follows: Year ended December 31, 2017 2016 2015 Net income $ 30,948 $ 19,720 $ 8,167 Weighted average shares of common stock outstanding: Basic 59,050 55,615 56,397 Dilutive effect of stock options, restricted stock, and performance stock units 1,974 898 449 Diluted 61,024 56,513 56,846 Earnings per share: Basic $ 0.52 $ 0.35 $ 0.14 Diluted $ 0.51 $ 0.35 $ 0.14

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories	December 31, 2017 2016 Raw materials $ 10,299 $ 5,399 Work in process 199 1,034 Finished goods 8,845 5,366 $ 19,343 $ 11,799

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	December 31, 2017 2016 Land $ 1,118 $ 1,118 Buildings and improvements 20,726 20,179 Machinery and equipment 26,685 22,764 Computer equipment and software 9,131 8,357 Furniture and fixtures 2,194 2,113 Construction in progress 897 1,569 60,751 56,100 Less accumulated depreciation (39,379 ) (36,067 ) $ 21,372 $ 20,033

Goodwill and Other Intangible26

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Goodwill	The changes in goodwill are as follows: December 31, 2017 2016 Balance as of January 1 $ 18,793 $ 18,250 Change related to foreign currency translation 1,290 543 Balance as of December 31 $ 20,083 $ 18,793
Summary of Intangible Assets	Intangible assets consist of the following: December 31, 2017 Amortization Gross Accumulated Net Customer list 10 $ 9,960 $ (6,122 ) $ 3,838 Patents and product rights 10 5,400 (4,258 ) 1,142 Acquired technology 7 7,737 (6,690 ) 1,047 Tradename 15 3,818 (1,622 ) 2,196 $ 26,915 $ (18,692 ) $ 8,223 December 31, 2016 Amortization Gross Accumulated Net Customer list 10 $ 9,321 $ (4,830 ) $ 4,491 Patents and product rights 10 5,400 (3,808 ) 1,592 Acquired technology 7 7,240 (5,279 ) 1,961 Tradename 15 3,573 (1,280 ) 2,293 $ 25,534 $ (15,197 ) $ 10,337
Summary of Patents and Products Rights	Patents and products rights are made up of the following: December 31, 2017 2016 HIV-related $ 900 $ 900 HCV-related 4,500 4,500 5,400 5,400 Less accumulated amortization (4,258 ) (3,808 ) $ 1,142 $ 1,592
Summary of Amortization Expense	Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows: 2018 $ 2,639 2019 1,626 2020 1,417 2021 1,173 2022 246 Beyond 1,122 $ 8,223

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	December 31, 2017 December 31, 2016 Payroll and related benefits $ 9,265 $ 7,685 Income taxes payable (receivable) 6,469 (39 ) Professional fees 1,064 982 Royalties 845 715 Other 3,052 1,971 $ 20,695 $ 11,314

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Income Tax Expense (Benefit)	Income before income tax expense consists of the following: Years Ended December 31, 2017 2016 2015 United States $ 2,270 $ 18,492 $ 5,302 Canada 38,762 1,831 3,530 $ 41,032 $ 20,323 $ 8,832
Components of Income Tax Expense (Benefit)	The components of income tax expense are as follows: Years Ended December 31, 2017 2016 2015 Current Federal $ — $ — $ — State — 250 — Canada 10,733 882 617 10,733 1,132 617 Deferred Federal 10,297 6,508 1,511 State (827 ) 569 311 Canada (649 ) (529 ) 48 8,821 6,548 1,870 Decrease in valuation allowance (9,470 ) (7,077 ) (1,822 ) (649 ) (529 ) 48 Total income tax expense $ 10,084 $ 603 $ 665
Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate	A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2017, 2016, and 2015 is as follows: 2017 2016 2015 Statutory U.S. federal income tax rate 34.0 % 34.0 % 34.0 % Deemed repatriation tax 7.8 — — Statutory rate change, deferred tax impact 29.4 — — Excess tax benefits for share-based payment awards (16.0 ) — — Tax effect of Canadian items (9.8 ) (4.9 ) (13.1 ) State income taxes, net of federal benefit (1.1 ) 2.0 1.5 Nondeductible expenses and other 3.4 6.7 5.7 Change in valuation allowance, federal and state (23.1 ) (34.8 ) (20.6 ) Effective tax rate 24.6 % 3.0 % 7.5 %
Components of Total Deferred Tax Assets (Liabilities)	Significant components of our deferred tax assets (liabilities) as of December 31, 2017 and 2016 are as follows: 2017 2016 Deferred tax assets (liabilities): Net operating loss carryforwards $ 15,338 $ 17,673 Inventories 1,179 1,680 Capitalized research and development costs 2,402 4,711 Accruals and reserves currently not deductible 3,103 3,282 Acquired intangible assets (1,825 ) (2,268 ) Depreciation and amortization (621 ) (212 ) Stock-based compensation 976 6,110 Tax credit carryforwards 6,722 1,751 Net deferred tax asset 27,274 32,727 Valuation allowance (29,225 ) (35,173 ) Net deferred tax liability $ (1,951 ) $ (2,446 )
Expiry Details of Federal Net Operating Losses Carryforwards	Our Federal NOL carryforwards expire as follows: Year of Expiration NOLs 2020 - 2025 $ 16,268 2026 - 2030 11,956 2031 - 2037 37,937 $ 66,161
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	A reconciliation of our unrecognized tax benefits is as follows: 2017 2016 2015 Balance as of January 1 $ 2,084 $ 2,088 $ 2,073 Additions for tax positions of prior periods — — 22 Reductions for tax positions of prior periods (421 ) (4 ) (7 ) Balance as of December 31 $ 1,663 $ 2,084 $ 2,088

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Weighted-Average Assumptions for Fair Value Measurement	The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions: Years Ended December 31, Black-Scholes Option Valuation Assumptions 2017 2016 2015 Risk-free interest rate (1) 2.22 % 1.76 % 1.49 % Expected dividend yield — — — Expected stock price volatility (2) 43 % 46 % 51 % Expected life of stock options (in years) (2) 7 7 7 (1) Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options. (2) Based upon historical experience.
Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options	Compensation expense recognized in the financial statements related to stock options was as follows: Years Ended December 31, 2017 2016 2015 Total compensation cost during the year $ 2,045 $ 2,691 $ 3,403 Amounts capitalized into inventory during the year (371 ) (270 ) (153 ) Amounts recognized in cost of products sold for amounts previously capitalized 276 212 153 Amounts charged against income $ 1,950 $ 2,633 $ 3,403
Summary of Company's Stock Option Activity	The following table summarizes the stock option activity under the Stock Plan: Options Weighted-Average Weighted-Average Aggregate Outstanding on January 1, 2015 5,740 $ 7.22 Granted 773 9.28 Exercised (74 ) 5.46 Expired (163 ) 8.55 Forfeited (60 ) 8.07 Outstanding on December 31, 2015 6,216 7.46 Granted 347 6.00 Exercised (405 ) 6.57 Expired (479 ) 9.17 Forfeited (223 ) 7.31 Outstanding on December 31, 2016 5,456 7.28 Granted 231 9.92 Exercised (4,413 ) 7.20 Expired (27 ) 8.36 Forfeited (46 ) 7.79 Outstanding on December 31, 2017 1,201 $ 8.04 6.5 $ 12,986 Vested or expected to vest as of December 31, 2017 1,201 $ 8.04 6.5 $ 12,986 Exercisable on December 31, 2017 659 $ 7.81 5.2 $ 7,280
Schedule of Currently Outstanding and Exercisable Stock Options	The following table summarizes information about stock options outstanding as of December 31, 2017: Options outstanding Options exercisable Range of exercise prices Number Weighted- (in years) Weighted- Number Weighted- $2.79 -$5.19 19 0.3 $ 3.46 19 $ 3.46 $5.37 158 8.0 5.37 45 5.37 $5.47 3 7.7 5.47 1 5.47 $5.71 149 5.9 5.71 116 5.71 $5.79 - $7.05 138 4.5 6.73 130 6.74 $7.28 - $8.33 122 6.4 7.81 95 7.74 $8.33 - $8.63 41 1.9 8.62 41 8.62 $8.87 167 8.9 8.87 — 0.00 $8.93 6 9.0 8.93 — 0.00 $9.31 - $14.95 398 6.5 10.32 212 10.40 1,201 6.5 $ 8.04 659 $ 7.81
Summary of Restricted Stock Award Activity under Stock Plan	The following table summarizes restricted stock award activity under the Stock Plan: Units Weighted-Average Issued and unvested, January 1, 2015 707 $ 6.50 Granted 362 8.25 Vested (354 ) 6.94 Forfeited (18 ) 8.01 Issued and unvested, December 31, 2015 697 7.14 Granted 632 5.63 Vested (446 ) 6.65 Forfeited (133 ) 6.43 Issued and unvested, December 31, 2016 750 6.28 Granted 329 9.77 Vested (378 ) 6.47 Forfeited (30 ) 7.57 Issued and unvested, December 31, 2017 671 $ 7.83 Issued and expected to vest, December 31, 2017 671 $ 7.83
Performance Based Restricted Stock Unit [Member]
Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan	The following table summarizes PSU activity under the Stock Plan: Units Weighted- Issued and unvested, January 1, 2017 456 5.46 Granted 424 8.19 Vested 0 0.00 Forfeited (28 ) 6.71 Issued and unvested, December 31, 2017 852 $ 6.78 Issued and expected to vest, December 31, 2017 852 $ 6.78

Business Segment Information (T

Business Segment Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Summary of Operating Segment and Asset Information	The following table summarizes operating segment information for the years ended December 31, 2017, 2016, and 2015, and asset information as of December 31, 2017 and 2016: Years Ended December 31, 2017 2016 2015 Net revenues: OSUR $ 91,965 $ 95,984 $ 89,795 DNAG 75,099 32,214 29,924 Total $ 167,064 $ 128,198 $ 119,719 Operating income (loss): OSUR $ (2,706 ) $ 15,606 $ 3,558 DNAG 42,944 4,659 4,500 Total $ 40,238 $ 20,265 $ 8,058 Depreciation and amortization: OSUR $ 3,170 $ 2,751 $ 3,015 DNAG 3,232 2,889 2,791 Total $ 6,402 $ 5,640 $ 5,806 Capital expenditures: OSUR $ 2,752 $ 2,145 $ 1,645 DNAG 1,585 2,208 2,099 Total $ 4,337 $ 4,353 $ 3,744 December 31, 2017 2016 Total assets: OSUR $ 192,352 $ 151,719 DNAG 103,849 56,216 Total $ 296,201 $ 207,935
Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area	The following table represents total net revenues by geographic area, based on the location of the customer: Years Ended December 31, 2017 2016 2015 United States $ 121,458 $ 99,758 $ 96,522 Europe 11,827 11,646 13,535 Other regions 33,779 16,794 9,662 $ 167,064 $ 128,198 $ 119,719 The following table represents total long-lived assets by geographic area: December 31, 2017 2016 United States $ 16,160 $ 15,737 Canada 5,083 4,286 Other regions 129 10 $ 21,372 $ 20,033

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule for Future Minimum Lease Payments under Operating Lease Agreements	We lease office space for our Canadian subsidiary and domestic warehouse facilities under operating lease agreements. Future payments required under these non-cancelable 2018 $ 617 2019 791 2020 828 2021 834 2022 845 Thereafter 1,242 $ 5,157
Schedule of Outstanding Non-cancelable Purchase Commitments	As of December 31, 2017, we had outstanding non-cancelable 2018 14,262 2019 383 2020 383 $ 15,028

Quarterly Data (Tables)

Quarterly Data (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Results of Operations	The following tables summarize the quarterly results of operations for each of the quarters in 2017 and 2016. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein. 2017 Results Three months ended March 31, June 30, September 30, December 31, Net revenues $ 32,546 $ 40,176 $ 42,314 $ 52,028 Costs and expenses 16,675 (1) 33,289 34,995 41,867 Operating income 15,871 (1) 6,887 7,319 10,161 Other income, net 467 96 113 118 Income before income taxes 16,338 6,983 7,432 10,279 Income tax expense 3,897 1,555 1,669 2,963 Net income $ 12,441 $ 5,428 $ 5,763 $ 7,316 Earnings per share Basic $ 0.22 $ 0.09 $ 0.10 $ 0.12 (2) Diluted $ 0.21 $ 0.09 $ 0.09 $ 0.12 (2) 2016 Results Three months ended March 31, June 30, September 30, December 31, Net revenues $ 29,089 $ 31,359 $ 32,251 (3) $ 35,499 (3) Costs and expenses 26,390 27,010 26,107 28,426 Operating income 2,699 4,349 6,144 7,073 Other income (expense), net (192 ) (340 ) 498 92 Income before income taxes 2,507 4,009 6,642 7,165 Income tax expense (benefit) 61 173 400 (31 ) Net income $ 2,446 $ 3,836 $ 6,242 $ 7,196 Earnings per share Basic $ 0.04 $ 0.07 $ 0.11 $ 0.13 Diluted $ 0.04 $ 0.07 $ 0.11 $ 0.13 (1) Includes a $12,500 gain associated with the settlement of our litigation with Ancestry.com DNA LLC and its contract manufacturer, which was recorded as a reduction of operating expenses in the indicated period. (2) The summation of the quarterly amounts may not equal the year-end (3) Revenues in the last six months of 2016 include an additional $5,436 of exclusivity payments recognized in other revenues as a result of the early termination of our HCV co-promotion

The Company - Additional Inform

The Company - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of segments of company	2

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands

Dec. 31, 2017USD ($)Supplier

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Jun. 12, 2015USD ($)

Jul. 31, 2017USD ($)

Jun. 30, 2017USD ($)Country

May 31, 2017USD ($)

Aug. 31, 2016USD ($)

Sep. 30, 2015USD ($)

Dec. 31, 2017USD ($)Suppliershares

Dec. 31, 2016USD ($)shares

Dec. 31, 2015USD ($)shares

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Income taxes paid

$ 4,309,000

$ 1,123,000

$ 719,000

Increase or decrease in allowance for doubtful accounts

172,000

40,000

341,000

Write-offs against allowance for doubtful accounts

200,000

369,000

0

Accruals for purchases of property and equipment

$ 449,000

$ 302,000

$ 1,256,000

Revenue recognized

0

18,951,000

13,479,000

Maximum value of grant revenue from clinical and regulatory activities

$ 10,400,000

$ 16,600,000

Initial grant revenue from clinical and regulatory activities

1,800,000

7,000,000

Remaining grant revenue from clinical and regulatory activities

$ 8,600,000

$ 9,600,000

Period of grant

3 years

6 years

Additional contract revenue from clinical and regulatory activities

$ 1,330,000

$ 2,600,000

$ 7,200,000

Contract revenues from clinical and regulatory activities

2,388,000

616,000

Reserve for sales return and allowances

217,000

217,000

Deferred revenue

1,314,000

1,388,000

1,314,000

1,388,000

Advertising expenses

717,000

626,000

623,000

Net foreign exchange (losses) gains

(1,442,000)

(607,000)

$ 1,005,000

Accumulated foreign currency adjustments included in other comprehensive loss amounted

9,787,000

14,220,000

9,787,000

14,220,000

Unrealized loss on marketable securities

(553,000)

Cash and cash equivalents

71,029,000

107,959,000

71,029,000

107,959,000

Fair value of plan assets

3,514,000

1,980,000

3,514,000

1,980,000

ASU 2014-09 [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative effect of retained earnings

163,000

Ora Quick HIV Self Test [Member] | Bill & Melinda Gates Foundation [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Charitable support agreement term

4 years

Number of countries in which products are sold | Country

50

Maximum amount of funding over the agreement period

$ 20,000,000

Funding received per year

$ 6,000,000

Support payments recognized in product revenue

1,047,000

Support payments recognized in other revenue

$ 689,000

Charitable support agreement commencement date

2017-06

Money Market Fund [Member] | Level I Instruments [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cash and cash equivalents

40,760,000

83,704,000

$ 40,760,000

$ 83,704,000

Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Number of anti-dilutive securities excluded from EPS computation | shares

180

2,546

4,314

Up Front Payment Arrangement [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Deferred revenue

$ 1,314,000

$ 1,388,000

$ 1,314,000

$ 1,388,000

AbbVie [Member] | Collaborative Arrangement Co-promotion [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Expiration date of rights agreement

Dec. 31, 2016

Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Percentage of concentration risk

37.00%

15.00%

Customer [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Percentage of concentration risk

25.00%

Customer One [Member] | Net Consolidated Revenue [Member] | Customer Concentration Risk [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Percentage of concentration risk

15.00%

12.00%

Other [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Contract revenues from clinical and regulatory activities

$ 1,999,000

$ 1,707,000

$ 1,783,000

Certificates of Deposit [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Certificates of deposit maturity date

Jan. 15, 2018

Maximum [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Useful life of Intangible assets

15 years

Maximum [Member] | Buildings [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Estimated useful lives of assets

40 years

Maximum [Member] | Computer Equipment [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Estimated useful lives of assets

10 years

Maximum [Member] | Machinery and Equipment [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Estimated useful lives of assets

10 years

Maximum [Member] | Furniture and Fixtures [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Estimated useful lives of assets

10 years

Maximum [Member] | Certificates of Deposit [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Interest rate on certificates of deposit

1.03%

Minimum [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Useful life of Intangible assets

7 years

Minimum [Member] | Buildings [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Estimated useful lives of assets

20 years

Minimum [Member] | Computer Equipment [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Estimated useful lives of assets

2 years

Minimum [Member] | Machinery and Equipment [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Estimated useful lives of assets

2 years

Minimum [Member] | Furniture and Fixtures [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Estimated useful lives of assets

2 years

Minimum [Member] | Certificates of Deposit [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Interest rate on certificates of deposit

0.89%

DNA Genotek [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Number of third-party suppliers to manufacture DNAG's products | Supplier

2

2

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 104,271	$ 11,160
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(553)
Fair Value	103,718	11,160
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	22,261	11,160
Gross Unrealized Gains	0	0
Fair Value	22,261	$ 11,160
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	82,010
Gross Unrealized Gains	0
Gross Unrealized Losses	(553)
Fair Value	81,457
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	83,403
Gross Unrealized Gains	0
Gross Unrealized Losses	(375)
Fair Value	83,028
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	20,868
Gross Unrealized Gains	0
Gross Unrealized Losses	(178)
Fair Value	$ 20,690

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
NET INCOME	$ 7,316	$ 5,763	$ 5,428	$ 12,441	$ 7,196	$ 6,242	$ 3,836	$ 2,446	$ 30,948	$ 19,720	$ 8,167
Weighted average shares of common stock outstanding:
BASIC									59,050	55,615	56,397
Dilutive effect of stock options, restricted stock, and performance stock units									1,974	898	449
Diluted									61,024	56,513	56,846
BASIC	$ 0.12	$ 0.10	$ 0.09	$ 0.22	$ 0.13	$ 0.11	$ 0.07	$ 0.04	$ 0.52	$ 0.35	$ 0.14
DILUTED	$ 0.12	$ 0.09	$ 0.09	$ 0.21	$ 0.13	$ 0.11	$ 0.07	$ 0.04	$ 0.51	$ 0.35	$ 0.14

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory, Net [Abstract]
Raw materials	$ 10,299	$ 5,399
Work in process	199	1,034
Finished goods	8,845	5,366
Inventories	$ 19,343	$ 11,799

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 60,751	$ 56,100
Less accumulated depreciation	(39,379)	(36,067)
Property plant and equipment Net	21,372	20,033
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	20,726	20,179
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	26,685	22,764
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	9,131	8,357
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	2,194	2,113
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 897	$ 1,569

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,434	$ 3,149	$ 2,992

Goodwill and Other Intangible40

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Roll Forward]
Beginning Balance	$ 18,793	$ 18,250
Change related to foreign currency translation	1,290	543
Ending Balance	$ 20,083	$ 18,793

Goodwill and Other Intangible41

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 26,915	$ 25,534
Intangible Assets, Accumulated Amortization	(18,692)	(15,197)
Intangible Assets, Net	$ 8,223	$ 10,337
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 9,960	$ 9,321
Intangible Assets, Accumulated Amortization	(6,122)	(4,830)
Intangible Assets, Net	$ 3,838	$ 4,491
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 5,400	$ 5,400
Intangible Assets, Accumulated Amortization	(4,258)	(3,808)
Intangible Assets, Net	$ 1,142	$ 1,592
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years	7 years
Intangible Assets, Gross	$ 7,737	$ 7,240
Intangible Assets, Accumulated Amortization	(6,690)	(5,279)
Intangible Assets, Net	$ 1,047	$ 1,961
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years	15 years
Intangible Assets, Gross	$ 3,818	$ 3,573
Intangible Assets, Accumulated Amortization	(1,622)	(1,280)
Intangible Assets, Net	$ 2,196	$ 2,293

Goodwill and Other Intangible42

Goodwill and Other Intangible Assets - Summary of Patents and Products Rights (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	$ 26,915	$ 25,534
Less accumulated amortization	(18,692)	(15,197)
Patent and products right, Net	8,223	10,337
HIV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	900	900
HCV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	4,500	4,500
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	5,400	5,400
Less accumulated amortization	(4,258)	(3,808)
Patent and products right, Net	$ 1,142	$ 1,592

Goodwill and Other Intangible43

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2,641	$ 2,538	$ 2,704

Goodwill and Other Intangible44

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,018	$ 2,639
2,019	1,626
2,020	1,417
2,021	1,173
2,022	246
Beyond	1,122
Intangible Assets, Net	$ 8,223	$ 10,337

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$ 9,265	$ 7,685
Income taxes payable (receivable)	6,469	(39)
Professional fees	1,064	982
Royalties	845	715
Other	3,052	1,971
Accrued Expenses, Total	$ 20,695	$ 11,314

Credit Facility - Additional In

Credit Facility - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 10,000,000
Line of credit facility, collateral	Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
Borrowings	$ 0	$ 0
Unused capacity commitment fee	0.375%
Maturity date of credit facility	Sep. 30, 2019
Maximum [Member]
Line of Credit Facility [Line Items]
Additional revolving commitments	$ 5,000,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio	110.00%
Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	2.50%
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 2,500,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]
United States									$ 2,270	$ 18,492	$ 5,302
Canada									38,762	1,831	3,530
Income before income taxes	$ 10,279	$ 7,432	$ 6,983	$ 16,338	$ 7,165	$ 6,642	$ 4,009	$ 2,507	$ 41,032	$ 20,323	$ 8,832

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current
Federal									$ 0	$ 0	$ 0
State										250
Canada									10,733	882	617
Total current income tax expense (benefit)									10,733	1,132	617
Deferred
Federal									10,297	6,508	1,511
State									(827)	569	311
Canada									(649)	(529)	48
Total deferred income tax expense (benefit)									8,821	6,548	1,870
(Decrease) increase in valuation allowance									(9,470)	(7,077)	(1,822)
Deferred income taxes									(649)	(529)	48
Total income tax expense	$ 2,963	$ 1,669	$ 1,555	$ 3,897	$ (31)	$ 400	$ 173	$ 61	$ 10,084	$ 603	$ 665

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 01, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Foreign income tax expense			$ 10,084	$ 353	$ 665
Effective income tax rate			34.00%	34.00%	34.00%
U.S. federal income tax benefits			$ 0	$ 0	$ 0
Decrease in valuation allowance			(9,470)	(7,077)	(1,822)
Increase valuation allowance associated with tax benefit	$ 3,391
Gross unrecognized tax benefits			$ 1,663	$ 2,084	$ 2,088	$ 2,073
Accounting Standards Update 2016-09 [Member]
Income Taxes [Line Items]
Cumulative effect of retained earnings	$ 3,391
Scenario, Forecast [Member]
Income Taxes [Line Items]
Effective income tax rate		21.00%

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	34.00%	34.00%	34.00%
Deemed repatriation tax	7.80%
Statutory rate change, deferred tax impact	29.40%
Excess tax benefits for share-based payment awards	(16.00%)
Tax effect of Canadian items	(9.80%)	(4.90%)	(13.10%)
State income taxes, net of federal benefit	(1.10%)	2.00%	1.50%
Nondeductible expenses and other	3.40%	6.70%	5.70%
Change in valuation allowance, federal and state	(23.10%)	(34.80%)	(20.60%)
Effective tax rate	24.60%	3.00%	7.50%

Income Taxes - Components of To

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 15,338	$ 17,673
Inventories	1,179	1,680
Capitalized research and development costs	2,402	4,711
Accruals and reserves currently not deductible	3,103	3,282
Acquired intangible assets	(1,825)	(2,268)
Depreciation and amortization	(621)	(212)
Stock-based compensation	976	6,110
Tax credit carryforwards	6,722	1,751
Net deferred tax asset	27,274	32,727
Valuation allowance	(29,225)	(35,173)
Net deferred tax liability	$ (1,951)	$ (2,446)

Income Taxes - Expiry Details o

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 66,161
2020 - 2025 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	16,268
2026 - 2030 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	11,956
2031 - 2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 37,937

Income Taxes - Reconciliation53

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance as of January 1	$ 2,084	$ 2,088	$ 2,073
Additions for tax positions of prior periods			22
Reductions for tax positions of prior periods	(421)	(4)	(7)
Balance as of December 31	$ 1,663	$ 2,084	$ 2,088

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan	4,355,000
Proceeds from exercise of stock options	$ 31,675,000	$ 2,656,000	$ 404,000
Income tax benefit realized from stock option exercises during period	0	0	0
Total compensation cost	6,973,000	6,063,000	6,045,000
Amount share repurchase program of common shares				$ 25,000,000
Total cost of common stock purchased and retired	$ 1,240,000	$ 3,444,000	$ 6,090,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	423	777
Average price of common stock		$ 6.29	$ 6.34
Total cost of common stock purchased and retired		$ 2,660,000	$ 4,926,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price	75.00%
Granted exercise periods	10 years
Vesting period	4 years
Vesting of Options	Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Weighted-average grant date fair value of stock options granted	$ 4.71	$ 2.91	$ 4.86
Aggregate intrinsic value of options exercised	$ 35,631,000	$ 763,000	$ 329,000
Unrecognized compensation expense related to unvested option awards	$ 1,950,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 10 months 25 days
Proceeds from exercise of stock options	$ 31,675,000	2,656,000	404,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 8 months 12 days
Total compensation cost	$ 2,705,000	$ 2,861,000	$ 2,642,000
Unrecognized compensation expense related to unvested restricted stock awards	$ 2,910,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations	130,000	132,000	133,000
Restricted shares of common stock and stock options, aggregate values	$ 1,240,000	$ 784,000	$ 1,164,000
Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 2,223,000	$ 511,000

Stockholders' Equity - Weighted

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	2.22%	1.76%	1.49%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	43.00%	46.00%	51.00%
Expected life of stock options (in years)	7 years	7 years	7 years

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Total compensation cost during the year	$ 2,045	$ 2,691	$ 3,403
Amounts capitalized into inventory during the year	(371)	(270)	(153)
Amounts recognized in cost of products sold for amounts previously capitalized	276	212	153
Amounts charged against income	$ 1,950	$ 2,633	$ 3,403

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning Balance	5,456	6,216	5,740
Options, Granted	231	347	773
Options, Exercised	(4,413)	(405)	(74)
Options, Expired	(27)	(479)	(163)
Options, Forfeited	(46)	(223)	(60)
Options, Outstanding, Ending Balance	1,201	5,456	6,216
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 7.28	$ 7.46	$ 7.22
Options, Vested or expected to vest	1,201
Weighted-Average Exercise Price Per Share, Granted	$ 9.92	6	9.28
Options, Exercisable	659
Weighted-Average Exercise Price Per Share, Exercised	$ 7.20	6.57	5.46
Weighted-Average Exercise Price Per Share, Expired	8.36	9.17	8.55
Weighted-Average Exercise Price Per Share, Forfeited	7.79	7.31	8.07
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance	8.04	$ 7.28	$ 7.46
Weighted-Average Exercise Price Per Share, Vested or expected to vest	8.04
Weighted-Average Exercise Price Per Share, Exercisable	$ 7.81
Weighted-Average Remaining Contractual Term, Outstanding	6 years 6 months
Weighted-Average Remaining Contractual Term, Vested or expected to vest	6 years 6 months
Weighted-Average Remaining Contractual Term, Exercisable	5 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 12,986
Aggregate Intrinsic Value, Vested or expected to vest	12,986
Aggregate Intrinsic Value, Exercisable	$ 7,280

Stockholders' Equity - Schedu58

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding | shares	1,201
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.04
Number Exercisable, Options exercisable | shares	659
Weighted-Average Exercise Price Per Share, Options exercisable	$ 7.81
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	2.79
Range of exercise prices, Upper Range Limit	$ 5.19
Number Outstanding, Options outstanding | shares	19
Weighted-Average Remaining Contractual Term (in years), Options outstanding	3 months 19 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 3.46
Number Exercisable, Options exercisable | shares	19
Weighted-Average Exercise Price Per Share, Options exercisable	$ 3.46
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.37
Number Outstanding, Options outstanding | shares	158
Weighted-Average Remaining Contractual Term (in years), Options outstanding	8 years
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.37
Number Exercisable, Options exercisable | shares	45
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.37
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.47
Number Outstanding, Options outstanding | shares	3
Weighted-Average Remaining Contractual Term (in years), Options outstanding	7 years 8 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.47
Number Exercisable, Options exercisable | shares	1
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.47
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.71
Number Outstanding, Options outstanding | shares	149
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 10 months 25 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.71
Number Exercisable, Options exercisable | shares	116
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.71
Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.79
Range of exercise prices, Upper Range Limit	$ 7.05
Number Outstanding, Options outstanding | shares	138
Weighted-Average Remaining Contractual Term (in years), Options outstanding	4 years 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$ 6.73
Number Exercisable, Options exercisable | shares	130
Weighted-Average Exercise Price Per Share, Options exercisable	$ 6.74
Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	7.28
Range of exercise prices, Upper Range Limit	$ 8.33
Number Outstanding, Options outstanding | shares	122
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 4 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 7.81
Number Exercisable, Options exercisable | shares	95
Weighted-Average Exercise Price Per Share, Options exercisable	$ 7.74
Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	8.33
Range of exercise prices, Upper Range Limit	$ 8.63
Number Outstanding, Options outstanding | shares	41
Weighted-Average Remaining Contractual Term (in years), Options outstanding	1 year 10 months 25 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.62
Number Exercisable, Options exercisable | shares	41
Weighted-Average Exercise Price Per Share, Options exercisable	$ 8.62
Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 8.87
Number Outstanding, Options outstanding | shares	167
Weighted-Average Remaining Contractual Term (in years), Options outstanding	8 years 10 months 25 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.87
Weighted-Average Exercise Price Per Share, Options exercisable	0
Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 8.93
Number Outstanding, Options outstanding | shares	6
Weighted-Average Remaining Contractual Term (in years), Options outstanding	9 years
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.93
Weighted-Average Exercise Price Per Share, Options exercisable	0
Range Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	9.31
Range of exercise prices, Upper Range Limit	$ 14.95
Number Outstanding, Options outstanding | shares	398
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.32
Number Exercisable, Options exercisable | shares	212
Weighted-Average Exercise Price Per Share, Options exercisable	$ 10.40

Stockholders' Equity - Summar59

Stockholders' Equity - Summary of Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Restricted Stock [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	750	697	707
Shares, Granted	329	632	362
Shares, Vested	(378)	(446)	(354)
Shares, Forfeited	(30)	(133)	(18)
Shares, Issued and unvested, Ending Balance	671	750	697
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance	$ 6.28	$ 7.14	$ 6.50
Shares, Issued and expected to vest	671
Weighted-Average Grant Date Fair Value, Granted	$ 9.77	5.63	8.25
Weighted-Average Grant Date Fair Value, Vested	6.47	6.65	6.94
Weighted-Average Grant Date Fair Value, Forfeited	7.57	6.43	8.01
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance	7.83	$ 6.28	$ 7.14
Weighted-Average Grant Date Fair Value, Issued and expected to vest	$ 7.83

Stockholders' Equity - Summar60

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance | shares	456
Shares, Granted | shares	424
Shares, Vested | shares	0
Shares, Forfeited | shares	(28)
Shares, Issued and unvested, Ending Balance | shares	852
Shares, Issued and expected to vest | shares	852
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance | $ / shares	$ 5.46
Weighted-Average Grant Date Fair Value, Granted | $ / shares	8.19
Weighted-Average Grant Date Fair Value, Vested | $ / shares	0
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	6.71
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance | $ / shares	6.78
Weighted-Average Grant Date Fair Value, Issued and expected to vest | $ / shares	$ 6.78

Business Segment Information -

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017Segment
Segment Reporting [Abstract]
Number of segments of company	2

Business Segment Information 62

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net revenues	$ 52,028	$ 42,314	$ 40,176	$ 32,546	$ 35,499	$ 32,251	$ 31,359	$ 29,089	$ 167,064	$ 128,198	$ 119,719
Operating income (loss)	10,161	$ 7,319	$ 6,887	$ 15,871	7,073	$ 6,144	$ 4,349	$ 2,699	40,238	20,265	8,058
Depreciation and amortization									6,402	5,640	5,806
Capital expenditures									4,337	4,353	3,744
Total assets	296,201				207,935				296,201	207,935
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues									91,965	95,984	89,795
Operating income (loss)									(2,706)	15,606	3,558
Depreciation and amortization									3,170	2,751	3,015
Capital expenditures									2,752	2,145	1,645
Total assets	192,352				151,719				192,352	151,719
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues									75,099	32,214	29,924
Operating income (loss)									42,944	4,659	4,500
Depreciation and amortization									3,232	2,889	2,791
Capital expenditures									1,585	2,208	$ 2,099
Total assets	$ 103,849				$ 56,216				$ 103,849	$ 56,216

Business Segment Information 63

Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 52,028	$ 42,314	$ 40,176	$ 32,546	$ 35,499	$ 32,251	$ 31,359	$ 29,089	$ 167,064	$ 128,198	$ 119,719
Long-lived assets	21,372				20,033				21,372	20,033
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									121,458	99,758	96,522
Long-lived assets	16,160				15,737				16,160	15,737
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									11,827	11,646	13,535
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									33,779	16,794	$ 9,662
Long-lived assets	129				10				129	10
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 5,083				$ 4,286				$ 5,083	$ 4,286

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Contractual Obligation Fiscal Year Maturity [Line Items]
Future minimum payments	$ 292
Rent expense	852	$ 715	$ 481
Employment Agreements [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Future minimum payments	1,729
Required salary payment as per agreements with employees, second year	330
Standby Letters of Credit [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Standby letters of credit	$ 1,840

Commitments and Contingencies65

Commitments and Contingencies - Schedule for Future Minimum Lease Payments under Operating Lease Agreements (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 617
2,019	791
2,020	828
2,021	834
2,022	845
Thereafter	1,242
Total	$ 5,157

Commitments and Contingencies66

Commitments and Contingencies - Schedule of Outstanding Non-cancelable Purchase Commitments (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Purchase Obligation, Fiscal Year Maturity [Abstract]
2,018	$ 14,262
2,019	383
2,020	383
Total	$ 15,028

Retirement Plans - Additional I

Retirement Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	617,000	$ 619,000	$ 587,000
Value of the assets associated with the plan	3,514,000	1,980,000
Total obligation under plan	3,514,000	1,980,000
RRSP [Member] | DNA Genotek [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	2,000
Contributed to plan, net of forfeitures	$ 145,000	$ 134,000	$ 134,000

Quarterly Data - Summary of Qua

Quarterly Data - Summary of Quarterly Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 52,028	$ 42,314	$ 40,176	$ 32,546	$ 35,499	$ 32,251	$ 31,359	$ 29,089	$ 167,064	$ 128,198	$ 119,719
Costs and expenses	41,867	34,995	33,289	16,675	28,426	26,107	27,010	26,390
Operating income	10,161	7,319	6,887	15,871	7,073	6,144	4,349	2,699	40,238	20,265	8,058
Other income, net	118	113	96	467	92	498	(340)	(192)	794	58	774
Income before income taxes	10,279	7,432	6,983	16,338	7,165	6,642	4,009	2,507	41,032	20,323	8,832
INCOME TAX EXPENSE	2,963	1,669	1,555	3,897	(31)	400	173	61	10,084	603	665
NET INCOME	7,316	5,763	5,428	12,441	7,196	6,242	3,836	2,446	30,948	19,720	8,167
Earnings per share
Net revenues	52,028	42,314	40,176	32,546	35,499	32,251	31,359	29,089	167,064	128,198	119,719
Costs and expenses	41,867	34,995	33,289	16,675	28,426	26,107	27,010	26,390
Operating income	10,161	7,319	6,887	15,871	7,073	6,144	4,349	2,699	40,238	20,265	8,058
Other income (expense), net	118	113	96	467	92	498	(340)	(192)	794	58	774
Income before income taxes	10,279	7,432	6,983	16,338	7,165	6,642	4,009	2,507	41,032	20,323	8,832
Income tax expense (benefit)	2,963	1,669	1,555	3,897	(31)	400	173	61	10,084	603	665
NET INCOME	$ 7,316	$ 5,763	$ 5,428	$ 12,441	$ 7,196	$ 6,242	$ 3,836	$ 2,446	$ 30,948	$ 19,720	$ 8,167
BASIC	$ 0.12	$ 0.10	$ 0.09	$ 0.22	$ 0.13	$ 0.11	$ 0.07	$ 0.04	$ 0.52	$ 0.35	$ 0.14
DILUTED	$ 0.12	$ 0.09	$ 0.09	$ 0.21	$ 0.13	$ 0.11	$ 0.07	$ 0.04	$ 0.51	$ 0.35	$ 0.14

Quarterly Data - Summary of Q69

Quarterly Data - Summary of Quarterly Results of Operations (Parenthetical) (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Gain on litigation settlement	$ 12,500
AbbVie [Member]
Payments recognized in other revenues	5,436
Ancestry.com DNA LLC and Its Contract Manufacturer Litigation [Member]
Gain on litigation settlement	$ 12,500

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Thousands	1 Months Ended
	Jan. 31, 2018USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company's new President and CEO	$ 8,590